Surrozen (NasdaqCM:SRZN) FY Conference Transcript

Summary of the Conference Call Company Overview - Company: Surrozen - Industry: Biotechnology, specifically focusing on retinal vascular diseases - Key Products: SZN-8141 and SZN-413, targeting Wnt biology and VEGF inhibition Core Points and Arguments Company Strengths - Surrozen combines expertise in Wnt biology with multivalent antibody technology, focusing on retinal vascular diseases [2][3] - Unique approach of combining Wnt, VEGF, and IL-6 inhibition in a single molecule, SZN-8141, which is currently the only known product to do so [2][3] Challenges - The company is in the execution phase, with an IND filing planned for 2026 [3] - Current therapies primarily slow disease progression rather than improve visual outcomes, highlighting the need for innovative solutions [3] Opportunities - Potential to improve visual and anatomic outcomes in diabetic macular edema and wet AMD [3] - The ability to stimulate normal vessel growth in the retina, which is a unique aspect of Wnt biology [4] Product Details - SZN-8141: An IgG-based multispecific molecule that activates Wnt signaling by binding to Fzd4 and LRP5 receptors, while also acting as a VEGF trap [9][10] - Preclinical data indicates that SZN-8141 shows synergistic benefits compared to existing therapies like EYLEA [12] Clinical Development - The first human trial design is still being finalized, with an emphasis on determining dosing and patient endpoints [18][19] - The company plans to conduct a phase 1b/2a study with ascending doses to evaluate visual acuity and retinal drying [19] Competitive Landscape - Merck's program, which is similar, has two phase 3 trials ongoing, with top-line data expected in September 2023 [26] - Surrozen aims to demonstrate that combining multiple mechanisms in one antibody will yield better outcomes than single-target therapies [27] Financial Aspects - Surrozen has a cash balance of approximately $80 million, with additional funding expected upon IND clearance [102] - The company is currently self-funding its clinical studies for SZN-8141 and SZN-8143, indicating a strong financial position for development [96] Safety and Risks - No theoretical risks associated with combining VEGF and Wnt inhibition have been identified, although immunogenicity risks are always a concern with large molecules [42][87] - Recent studies have shown some retinal vascular occlusions, but these are not deemed above the expected background rate [88] Future Directions - Surrozen plans to advance both SZN-8141 and SZN-8143, with SZN-8143 targeting more inflammatory-driven diseases [63][64] - The company is optimistic about the potential for IL-6 inhibition to provide additive benefits in retinal diseases [68][70] Additional Important Information - The market for retinal diseases is becoming increasingly attractive, with growing strategic interest from larger pharmaceutical companies [100][101] - Surrozen's strategy includes leveraging the small number of retinal specialists in the U.S. for commercialization, making it a tractable market for a small biotech firm [96][97]